Saturday, 22 September 2012

Pedia-Lax


Generic Name: senna (SEN nah)

Brand Names: Black Draught, Dr Caldwell Laxative, Ex-Lax Chocolated, Ex-Lax Maximum Relief Formula, Ex-Lax Regular Strength Pills, Fletchers Castoria, Innerclean, Pedia-Lax, Perdiem Overnight, Senexon, Senna, Senna Lax, Senna Smooth, Senna Soft, Senna-gen, Senokot, Senokot Extra, SenokotXTRA, SenoSol, SenoSol-X


What is Pedia-Lax (senna)?

Senna is also known as Cassia senna, tinnevelly senna, India senna, Alexandrian senna, and Khartoum senna.


Senna has been used in alternative medicine as an aid to treat constipation.


Not all uses for senna have been approved by the FDA. Senna should not be used in place of medication prescribed for you by your doctor.

Senna is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Senna may also be used for other purposes not listed in this product guide.


What is the most important information I should know about Pedia-Lax (senna)?


Not all uses for senna have been approved by the FDA. Senna should not be used in place of medication prescribed for you by your doctor.

Senna is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Use senna as directed on the label, or as your healthcare provider has prescribed. Do not use this product in larger amounts or for longer than recommended.


Call your healthcare provider if your symptoms do not improve, or if they get worse while using senna. Do not use this product for longer than 1 week without the advice of a healthcare provider.

What should I discuss with my health care provider before taking Pedia-Lax (senna)?


Ask a doctor, pharmacist, herbalist, or other healthcare provider if it is safe for you to use this product if you have:



  • a bowel disorder such as Crohn's disease or ulcerative colitis;




  • heart disease; or




  • stomach pain, nausea, or vomiting.



Before using senna, talk to your doctor, pharmacist, herbalist, or other healthcare provider. You may not be able to use senna if you have any other medical conditions, allergies, or if you take other medicines or herbal/health supplements.


Do not take senna without first talking to your doctor if you are pregnant or could become pregnant. Do not take senna without first talking to your doctor if you are breast-feeding a baby. Some forms of senna are made for use by children. Do not give any herbal/health supplement to a child without the advice of a doctor.

How should I take Pedia-Lax (senna)?


When considering the use of herbal supplements, seek the advice of your doctor. You may also consider consulting a practitioner who is trained in the use of herbal/health supplements.


If you choose to use senna, use it as directed on the package or as directed by your doctor, pharmacist, or other healthcare provider. Do not use more of this product than is recommended on the label.


Senna is usually taken before bed to produce a bowel movement 6 to 12 hours later when you wake up.


Do not use different forms (such as tablets and liquid) of senna at the same time unless your healthcare provider tells you to. Call your healthcare provider if your symptoms do not improve, or if they get worse while using senna. Do not use this product for longer than 1 week without the advice of a healthcare provider. Store senna at room temperature away from moisture, heat, and light.

What happens if I miss a dose?


Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Pedia-Lax (senna)?


Follow your healthcare provider's instructions about any restrictions on food, beverages, or activity.


Pedia-Lax (senna) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your healthcare provider at once if you have a serious side effect such as:

  • severe stomach pain, severe diarrhea, watery diarrhea;




  • weight loss;




  • worsening constipation after you stop taking senna;




  • enlargement of your fingers and toes;




  • low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling); or




  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).



Less serious side effects may include:



  • stomach cramps, bloating, gas, mild diarrhea;




  • numbness or tingly feeling;




  • joint pain; or




  • discolored urine.



This is not a complete list of side effects and others may occur. Tell your doctor, pharmacist, herbalist, or other healthcare provider about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Pedia-Lax (senna)?


Do not take senna without the advice of a healthcare provider if you are using any of the following medications:

  • digoxin (Lanoxin);




  • a diuretic (water pill); or




  • a blood thinner such as warfarin (Coumadin).



This list is not complete and other drugs may interact with senna. Tell your healthcare provider about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Pedia-Lax resources


  • Pedia-Lax Side Effects (in more detail)
  • Pedia-Lax Use in Pregnancy & Breastfeeding
  • Pedia-Lax Drug Interactions
  • Pedia-Lax Support Group
  • 0 Reviews for Pedia-Lax - Add your own review/rating


  • Senna Natural MedFacts for Professionals (Wolters Kluwer)

  • Senna Professional Patient Advice (Wolters Kluwer)

  • Senna Natural MedFacts for Consumers (Wolters Kluwer)

  • Senna Monograph (AHFS DI)

  • Senexon Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Senokot MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Pedia-Lax with other medications


  • Constipation


Where can I get more information?


  • Consult with a licensed healthcare professional before using any herbal/health supplement. Whether you are treated by a medical doctor or a practitioner trained in the use of natural medicines/supplements, make sure all your healthcare providers know about all of your medical conditions and treatments.

See also: Pedia-Lax side effects (in more detail)


Sunday, 16 September 2012

Sarafem


Generic Name: fluoxetine (Oral route)


floo-OX-e-teen hye-droe-KLOR-ide


Oral route(Capsule;Capsule, Delayed Release;Solution)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PROZAC(R) is approved for use in pediatric patients with MDD and obsessive compulsive disorder (OCD) .


Oral route(Tablet)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SARAFEM(R) is not approved for use in pediatric patients .



Commonly used brand name(s)

In the U.S.


  • Prozac

  • Prozac Weekly

  • Rapiflux

  • Sarafem

  • Selfemra

In Canada


  • Alti-Fluoxetine Hydrochloride

  • Fluoxetine

Available Dosage Forms:


  • Capsule

  • Capsule, Delayed Release

  • Tablet

  • Syrup

  • Solution

Therapeutic Class: Antidepressant


Pharmacologic Class: Fluoxetine


Uses For Sarafem


Fluoxetine is used to treat mental depression, obsessive-compulsive disorder (OCD), bulimia nervosa, premenstrual dysphoric disorder (PMDD), and panic disorder.


Fluoxetine is used with olanzapine to treat depression that is a part of bipolar disorder. These medicines are also used together to treat treatment resistant depression in patients who have been treated with other antidepressants that did not work well. This medicine may also be used for other conditions as determined by your doctor.


Fluoxetine belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs). These medicines are thought to work by increasing the activity of a chemical called serotonin in the brain.


This medicine is available only with your doctor's prescription.


Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, fluoxetine is used in certain patients with the following medical conditions:


  • Premature ejaculation.

Before Using Sarafem


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of fluoxetine in children with depression. However, safety and efficacy have not been established in children younger than 8 years of age.


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of fluoxetine in children with obsessive-compulsive disorder. However, safety and efficacy have not been established in children younger than 7 years of age.


Appropriate studies have not been performed on the relationship of age to the effects of fluoxetine in children with bulimia nervosa and panic disorder. Safety and efficacy have not been established.


Appropriate studies have not been performed on the relationship of age to the effects of olanzapine and fluoxetine combination in the pediatric population. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of fluoxetine in the elderly. However, elderly patients may be more sensitive to the effects of this medicine than younger adults, and are more likely to have hyponatremia (low sodium in the blood), which may require caution and an adjustment in the dose for patients receiving fluoxetine.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Bepridil

  • Clorgyline

  • Furazolidone

  • Iproniazid

  • Isocarboxazid

  • Levomethadyl

  • Linezolid

  • Mesoridazine

  • Methylene Blue

  • Metoclopramide

  • Moclobemide

  • Nialamide

  • Pargyline

  • Phenelzine

  • Pimozide

  • Procarbazine

  • Selegiline

  • Terfenadine

  • Thioridazine

  • Toloxatone

  • Tranylcypromine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Abciximab

  • Acecainide

  • Aceclofenac

  • Acemetacin

  • Acenocoumarol

  • Ajmaline

  • Alclofenac

  • Almotriptan

  • Amiodarone

  • Amisulpride

  • Amitriptyline

  • Amoxapine

  • Ancrod

  • Anisindione

  • Antithrombin III Human

  • Apazone

  • Aprindine

  • Ardeparin

  • Arsenic Trioxide

  • Aspirin

  • Astemizole

  • Azimilide

  • Benoxaprofen

  • Bivalirudin

  • Bretylium

  • Bromfenac

  • Bufexamac

  • Carprofen

  • Certoparin

  • Chloral Hydrate

  • Chloroquine

  • Chlorpromazine

  • Cilostazol

  • Citalopram

  • Clarithromycin

  • Clometacin

  • Clonixin

  • Clopidogrel

  • Dalteparin

  • Danaparoid

  • Defibrotide

  • Dermatan Sulfate

  • Desipramine

  • Desirudin

  • Desvenlafaxine

  • Dexfenfluramine

  • Dexketoprofen

  • Dextromethorphan

  • Dibenzepin

  • Diclofenac

  • Dicumarol

  • Diflunisal

  • Dipyridamole

  • Dipyrone

  • Disopyramide

  • Dofetilide

  • Dolasetron

  • Doxepin

  • Droperidol

  • Droxicam

  • Duloxetine

  • Eletriptan

  • Enflurane

  • Enoxaparin

  • Eptifibatide

  • Erythromycin

  • Escitalopram

  • Etodolac

  • Etofenamate

  • Felbinac

  • Fenbufen

  • Fenfluramine

  • Fenoprofen

  • Fentiazac

  • Flecainide

  • Floctafenine

  • Fluconazole

  • Flufenamic Acid

  • Fluoxetine

  • Flurbiprofen

  • Fluvoxamine

  • Fondaparinux

  • Foscarnet

  • Frovatriptan

  • Gemifloxacin

  • Halofantrine

  • Haloperidol

  • Halothane

  • Heparin

  • Hydroquinidine

  • Ibuprofen

  • Ibutilide

  • Imipramine

  • Indomethacin

  • Indoprofen

  • Isoflurane

  • Isoxicam

  • Isradipine

  • Ketoprofen

  • Ketorolac

  • Lidoflazine

  • Lorcainide

  • Lornoxicam

  • Magnesium Salicylate

  • Meclofenamate

  • Mefenamic Acid

  • Mefloquine

  • Meloxicam

  • Meperidine

  • Milnacipran

  • Mirtazapine

  • Nabumetone

  • Nadroparin

  • Naproxen

  • Naratriptan

  • Nepafenac

  • Niflumic Acid

  • Nimesulide

  • Nortriptyline

  • Octreotide

  • Oxaprozin

  • Oxyphenbutazone

  • Parnaparin

  • Paroxetine

  • Pentamidine

  • Pentosan Polysulfate Sodium

  • Phenindione

  • Phenprocoumon

  • Phenylbutazone

  • Pirazolac

  • Pirmenol

  • Piroxicam

  • Pirprofen

  • Prajmaline

  • Prasugrel

  • Probucol

  • Procainamide

  • Prochlorperazine

  • Propafenone

  • Propyphenazone

  • Proquazone

  • Quetiapine

  • Rasagiline

  • Reviparin

  • Rizatriptan

  • Salicylic Acid

  • Salsalate

  • Sematilide

  • Sertindole

  • Sertraline

  • Sibutramine

  • Sotalol

  • Spiramycin

  • St John's Wort

  • Sulfamethoxazole

  • Sulindac

  • Sultopride

  • Sumatriptan

  • Suprofen

  • Tamoxifen

  • Tapentadol

  • Tedisamil

  • Telithromycin

  • Tenidap

  • Tenoxicam

  • Tiaprofenic Acid

  • Ticlopidine

  • Tinzaparin

  • Tirofiban

  • Tolmetin

  • Tramadol

  • Trazodone

  • Trifluoperazine

  • Trimethoprim

  • Trimipramine

  • Tryptophan

  • Vasopressin

  • Venlafaxine

  • Vilazodone

  • Warfarin

  • Ziprasidone

  • Zolmitriptan

  • Zomepirac

  • Zotepine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Alprazolam

  • Bupropion

  • Buspirone

  • Carbamazepine

  • Clozapine

  • Cyclobenzaprine

  • Cyproheptadine

  • Delavirdine

  • Digoxin

  • Fluphenazine

  • Fosphenytoin

  • Galantamine

  • Ginkgo

  • Iloperidone

  • Lithium

  • Metoprolol

  • Nebivolol

  • Paroxetine

  • Pentazocine

  • Phenytoin

  • Risperidone

  • Ritonavir

  • Tetrabenazine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Bipolar disorder (mood disorder with alternating episodes of mania and depression), or risk of or

  • Bleeding problems or

  • Diabetes or

  • Glaucoma, narrow angle or

  • Hyponatremia (low sodium in the blood) or

  • Mania, history of or

  • Seizures, history of—Use with caution. May make these conditions worse.

  • Diseases affecting metabolism or diseases involving blood circulation—Caution should be used in patients with these medical problems.

  • Drug abuse, history of—Potential for increased dependence on this medicine.

  • Electroconvulsive therapy (ECT)—Use with caution. May cause prolonged seizures in patients receiving ECT treatment with fluoxetine.

  • Heart attack, recent history of or

  • Heart disease, unstable—The effects of fluoxetine in patients with these conditions are not known.

  • Kidney disease or

  • Liver disease—Use with caution. Higher blood levels of fluoxetine may occur, increasing the chance of side effects.

  • Weight loss—Fluoxetine may cause weight loss. This weight loss is usually small, but if a large weight loss occurs, it may be harmful in some patients especially in depressed or bulimic patients.

Proper Use of fluoxetine

This section provides information on the proper use of a number of products that contain fluoxetine. It may not be specific to Sarafem. Please read with care.


Take this medicine only as directed by your doctor, to benefit your condition as much as possible. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.


This medicine should come with a Medication Guide. It is very important that you read and understand this information. Be sure to ask your doctor about anything you do not understand.


If this medicine upsets your stomach, it may be taken with food.


If you are taking fluoxetine for depression, it may take 4 weeks or longer before you begin to feel better. Also, you may need to keep taking this medicine for 6 months or longer to stop the depression from returning.


If you are taking fluoxetine for obsessive-compulsive disorder, it may take 5 weeks or longer before you begin to get better. Your doctor should check your progress at regular visits during this time.


If you are taking fluoxetine for bulimia nervosa, you may begin to get better after 1 week. However, it may take 4 weeks or longer before you get better.


If you are using the oral liquid, shake the bottle well before measuring each dose. Use a small measuring cup or a measuring spoon to measure each dose. The teaspoons and tablespoons that are used for serving and eating food do not measure exact amounts.


Use only the brand of this medicine that your doctor prescribed. Different brands may not work the same way.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage forms (delayed-release capsules, pulvules, or solution):
    • For depression:
      • Adults—At first, 20 milligrams (mg) once a day, taken as a single dose in the morning. Your doctor may increase your dose as needed. However, the dose is usually not more than 80 mg per day. Once your depression is under control, your doctor may wish to change you to a weekly dose. In this case, you will usually take a 90-mg capsule as a single dose one day per week.

      • Children 8 years of age and older—At first, 10 to 20 mg once a day, taken as a single dose in the morning. Your doctor may increase your dose as needed.

      • Children younger than 8 years of age—Use and dose must be determined by your doctor.


    • For depression that occurs with bipolar disorder or treatment resistant depression:
      • Adults—At first, one capsule of 20 mg fluoxetine and 5 mg oral olanzapine once a day in the evening. Your doctor may increase your dose as needed. However, the dose is usually not more than 18 mg of oral olanzapine and 75 mg of fluoxetine per day.

      • Children—Use and dose must be determined by your doctor.


    • For bulimia nervosa:
      • Adults—60 milligrams (mg) once a day, taken as a single dose in the morning. Your doctor may start with a lower dose and increase it gradually. The dose is usually not more than 60 mg per day.

      • Children—Use and dose must be determined by your doctor.


    • For obsessive-compulsive disorder:
      • Adults—At first, usually 20 milligrams (mg) once a day, taken as a single dose in the morning. Your doctor may increase your dose as needed. However, the dose is usually not more than 80 mg per day.

      • Children 7 years of age and older—At first, 10 mg once a day, taken as a single dose in the morning. Your doctor may increase your dose as needed. However, the dose is usually not more than 60 mg per day.

      • Children younger than 7 years of age—Use and dose must be determined by your doctor.


    • For panic disorder:
      • Adults—At first, 10 milligrams (mg) once a day, taken as a single dose in the morning or evening for one week. Your doctor may increase your dose as needed. However, the dose is usually not more than 60 mg per day.

      • Children—Use and dose must be determined by your doctor.


    • For premenstrual dysphoric disorder:
      • Adults—At first, usually 20 milligrams (mg) once a day, taken as a single dose in the morning. Your doctor may have you take 20 mg every day of your menstrual cycle or for only 14 days out of your cycle. Your doctor will determine the use and dose that is right for you. Your doctor may increase your dose as needed. However, the dose is usually not more than 80 mg a day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using Sarafem


It is important that your doctor check your progress at regular visits, to allow changes in your dose and help reduce any side effects. Blood tests may be needed to check for unwanted effects.


Do not take fluoxetine within 2 weeks of taking an monoamine oxidase (MAO) inhibitor (e.g., isocarboxazid [Marplan®], phenelzine [Nardil®], selegiline [Eldepryl®], or tranylcypromine [Parnate®]). Do not take an MAO inhibitor for at least 5 weeks after taking fluoxetine. If you do, you may develop extremely high blood pressure or seizures.


Do not take thioridazine (Mellaril®) while you are taking fluoxetine or less than 5 weeks after you have stopped taking fluoxetine. You should not use pimozide (Orap®) while you are taking this medicine. Using these medicines together can cause very serious heart problems.


You should not take other medicines that also contain fluoxetine. This includes Symbyax®, Sarafem®, or Prozac® Weekly. Using these medicines together may increase your chance for more serious side effects.


If you develop a skin rash or hives, stop taking fluoxetine and check with your doctor as soon as possible.


Fluoxetine may cause some teenagers and young adults to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. Some people may have trouble sleeping, get upset easily, have a big increase in energy, or start to act reckless. If you or your caregiver notice any of these unwanted effects, tell your doctor right away. Let the doctor know if you, your child, or anyone in your family has bipolar disorder (manic-depressive) or has tried to commit suicide.


Do not stop suddenly taking this medicine without checking first with your doctor. If you have been instructed to stop taking fluoxetine, ask your doctor how to slowly decrease the dose. This is to decrease the chance of having symptoms such as agitation, breathing problems, chest pain, confusion, diarrhea, dizziness or lightheadedness, a fast heartbeat, headache, increased sweating, muscle pain, nausea, restlessness, runny nose, trouble with sleeping, trembling or shaking, unusual tiredness or weakness, vision changes, or vomiting.


Make sure your doctor knows about all the other medicines you are using. Fluoxetine may cause serious conditions such as serotonin syndrome and neuroleptic malignant syndrome (NMS)-like reactions when taken with certain medicines such as linezolid [Zyvox®], lithium, tryptophan, St. John's Wort, or some pain medicines (e.g., tramadol [Ultram®], rizatriptan [Maxalt®], sumatriptan [Imitrex®], or zolmitriptan [Zomig®]). Check with your doctor first before taking any other medicines.


Fluoxetine may increase your risk for bleeding problems. Make sure your doctor knows if you are also using other medicines that thin the blood, such as aspirin, pain or arthritis medicines, sometimes called “NSAIDs” (e.g., ibuprofen, naproxen, Advil®, Aleve®, Celebrex®, or Motrin®), or warfarin (Coumadin®).


Hyponatremia (low sodium in the blood) may occur with this medicine. Stop using the medicine and check with your doctor right away if you have confusion, difficulty concentrating, headaches, memory problems, weakness, and unsteadiness.


Avoid drinking alcohol while you are taking fluoxetine.


For diabetic patients:


  • This medicine may affect blood sugar levels. If you notice a change in the results of your blood or urine sugar tests or if you have any questions, check with your doctor.

This medicine may cause some people to become drowsy or less able to think clearly, or to have poor muscle control. Make sure you know how you react to fluoxetine before you drive, use machines, or do anything else that could be dangerous if you are not alert and well able to control your movements.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Sarafem Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Inability to sit still

  • restlessness

  • skin rash, hives, or itching

Less common
  • Chills or fever

  • joint or muscle pain

Rare
  • Anxiety

  • cold sweats

  • confusion

  • convulsions (seizures)

  • cool pale skin

  • diarrhea

  • difficulty with concentration

  • drowsiness

  • dryness of the mouth

  • excessive hunger

  • fast or irregular heartbeat

  • headache

  • increased sweating

  • increased thirst

  • lack of energy

  • mood or behavior changes

  • overactive reflexes

  • purple or red spots on the skin

  • racing heartbeat

  • shakiness or unsteady walk

  • shivering or shaking

  • talking, feeling, and acting with excitement and activity you cannot control

  • trouble with breathing

  • unusual or incomplete body or facial movements

  • unusual tiredness or weakness

Incidence not known
  • Abdominal or stomach pain

  • agitation

  • back or leg pains

  • bleeding gums

  • blindness

  • blistering, peeling, or loosening of the skin

  • bloating

  • blood in the urine or stools

  • bloody, black, or tarry stools

  • blue-yellow color blindness

  • blurred vision

  • chest pain or discomfort

  • clay-colored stools

  • constipation

  • continuing vomiting

  • cough or dry cough

  • dark urine

  • decreased urine output

  • decreased vision

  • depression

  • difficulty with breathing

  • difficulty with swallowing

  • dizziness or lightheadedness

  • eye pain

  • fainting

  • fast, pounding, or irregular heartbeat or pulse

  • general body swelling

  • high fever

  • high or low blood pressure

  • hives, itching, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue

  • hostility

  • indigestion

  • irregular or slow heart rate

  • irritability

  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

  • light-colored stools

  • loss of appetite

  • loss of bladder control

  • muscle twitching

  • nausea

  • nightmares

  • no blood pressure or pulse

  • noisy breathing

  • nosebleeds

  • pain in the ankles or knees

  • painful, red lumps under the skin, mostly on the legs

  • pains in the stomach, side, or abdomen, possibly radiating to the back

  • pinpoint red spots on the skin

  • rapid weight gain

  • red or irritated eyes

  • red skin lesions, often with a purple center

  • redness, tenderness, itching, burning, or peeling of the skin

  • severe muscle stiffness

  • severe sleepiness

  • shortness of breath

  • skin rash

  • slurred speech

  • sore throat

  • sores, ulcers, or white spots on the lips or in the mouth

  • stopping of heart

  • sudden shortness of breath or troubled breathing

  • sudden weakness in the arms or legs

  • sudden, severe chest pain

  • swelling of the face, ankles, or hands

  • swollen or painful glands

  • thoughts of killing oneself

  • tightness in the chest

  • tiredness

  • twitching, twisting, or uncontrolled repetitive movements of the tongue, lips, face, arms, or legs

  • unconsciousness

  • unpleasant breath odor

  • unusual bleeding or bruising

  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness

  • unusually pale skin

  • use of extreme physical or emotional force

  • vomiting of blood

  • wheezing

  • yellow eyes or skin

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Actions that are out of control

  • change in consciousness

  • change in near or distance vision

  • change in walking and balance

  • clumsiness or unsteadiness

  • confusion as to time, place, or person

  • decreased awareness or responsiveness

  • decreased interest in sexual intercourse

  • difficulty in focusing eyes

  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position

  • feeling of constant movement of self or surroundings

  • hallucinations

  • high or low blood pressure

  • holding false beliefs that cannot be changed by fact

  • inability to have or keep an erection

  • irregular heartbeat recurrent

  • loss in sexual ability, desire, drive, or performance

  • loss of bladder control

  • loss of consciousness

  • sensation of spinning

  • severe muscle stiffness

  • severe sleepiness

  • shakiness in the legs, arms, hands, or feet

  • sweating

  • talking, feeling, and acting with excitement

  • tiredness

  • trembling or shaking of the hands or feet

  • unresponsiveness

  • unusual excitement, nervousness, or restlessness

  • unusual or incomplete body or facial movements

  • unusually pale skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Decreased appetite

Less common or rare
  • Abnormal dreams

  • breast enlargement or pain

  • change in sense of taste

  • changes in vision

  • feeling of warmth or heat

  • flushing or redness of the skin, especially on face and neck

  • frequent urination

  • hair loss

  • increased appetite

  • increased sensitivity of the skin to sunlight

  • menstrual pain

  • stomach cramps, gas, or pain

  • unusual secretion of milk, in females

  • weight loss

  • yawning

Incidence not known
  • Cracks in the skin

  • loss of heat from the body

  • painful or prolonged erections of the penis

  • scaly skin

  • swelling of the breasts or breast soreness in both females and males

  • unusual milk production

After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:


  • Actions that are out of control

  • burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feeling

  • crying

  • depersonalization

  • dizziness

  • euphoria

  • feeling of distress

  • feeling that body or surroundings are turning

  • general feeling of discomfort or illness

  • paranoia

  • quick to react or overreact emotionally

  • rapidly changing moods

  • sleeplessness

  • sweating

  • unable to sleep

  • vaginal bleeding

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Sarafem side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Sarafem resources


  • Sarafem Side Effects (in more detail)
  • Sarafem Use in Pregnancy & Breastfeeding
  • Drug Images
  • Sarafem Drug Interactions
  • Sarafem Support Group
  • 9 Reviews for Sarafem - Add your own review/rating


  • Sarafem MedFacts Consumer Leaflet (Wolters Kluwer)

  • Sarafem Prescribing Information (FDA)

  • Fluoxetine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Fluoxetine Prescribing Information (FDA)

  • Fluoxetine Hydrochloride Monograph (AHFS DI)

  • Prozac Consumer Overview

  • Prozac Weekly Delayed-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Prozac Weekly Prescribing Information (FDA)

  • Selfemra Prescribing Information (FDA)



Compare Sarafem with other medications


  • Premenstrual Dysphoric Disorder

Saturday, 15 September 2012

Synagis


Generic Name: Palivizumab
Class: Monoclonal Antibodies
VA Class: AM800
CAS Number: 188039-54-5

Introduction

Antiviral; biosynthetic humanized form of a murine monoclonal antibody to the F surface glycoprotein of respiratory syncytial virus (RSV).1 2 3 4 5 6 7 8 50


Uses for Synagis


Respiratory Syncytial Virus (RSV) Infections


Prevention of serious RSV lower respiratory tract infections in infants at high risk for RSV disease.1 6 7 8 50 51


Recommended for infants <24 months of age who have chronic lung disease (e.g., bronchopulmonary dysplasia [BPD]), history of premature birth (gestational age ≤35 weeks), or hemodynamically significant congenital heart disease (CHD).1 6 7 8 50 51 May reduce severity of RSV infection and reduce frequency and duration of RSV-related hospitalizations in these high-risk infants.1 6 7 8 37 39 40 41 42 50 51


Drug of choice when RSV prophylaxis is indicated.6 7 8 50


Need for and efficacy of palivizumab prophylaxis following institutional RSV outbreaks† (e.g., in neonatal intensive care units) not studied to date; the major means of preventing RSV illness in such situations is strict observance of infection control practices.3 8 9


Safety and efficacy for treatment of established RSV disease not established.1 37 Do not use for treatment of RSV infection.1 8 50


Synagis Dosage and Administration


General



  • Administer first dose immediately prior to RSV season and additional doses once monthly throughout the season.1 3 8 In the northern hemisphere, RSV season typically commences in November and lasts through April, but may begin earlier or persist later in certain communities.1 3 8




  • AAP states that in most seasons and in most regions of the northern hemisphere, give first dose at beginning of November and the last dose at beginning of March; these 5 doses usually provide protection during the entire season.3 8 However, decisions about the specific duration of prophylaxis should be individualized according to the duration of the local RSV season.3 8




  • AAP recommends that clinicians consult local health departments or diagnostic virology laboratories or the CDC to determine the epidemiology of RSV in their area.8




  • If an infant receiving palivizumab prophylaxis becomes infected with RSV, continue giving the monthly prophylaxis doses for the duration of the RSV season.1 8 37



Administration


IM Administration


Administer IM,1 5 6 8 preferably in anterolateral aspect of the thigh.1 5 Avoid gluteal muscle because of risk of damage to sciatic nerve.1


Has been administered by IV infusion† over 3–5 minutes in a limited number of infants,4 but manufacturer states the currently available formulation is intended for IM injection only.1 37


Administer immediately after withdrawal from vial.1 Vial is for single use only; discard any unused portion.1


Doses involving volumes >1 mL should be divided and injected IM at different sites.1


Dosage


Pediatric Patients


Respiratory Syncytial Virus (RSV) Infections

Prevention of RSV Lower Respiratory Tract Infections

IM

Infants at high risk for RSV disease: 15 mg/kg once monthly.1 6 8 50 Give first dose prior to beginning of RSV season and subsequent doses once monthly until end of season.1 6 8


Infants at high risk for RSV undergoing cardiopulmonary bypass: Give a supplemental 15-mg/kg dose as soon as possible after cardiopulmonary bypass (even if this is <1 month after the last dose).1 8 51 (See Plasma Concentrations under Pharmacokinetics.) Thereafter, give usual doses once monthly.1 8


Cautions for Synagis


Contraindications



  • History of a severe reaction to the drug or any ingredient in the formulation (e.g., murine protein).1 37



Warnings/Precautions


Sensitivity Reactions


Hypersensitivity Reactions

Severe acute hypersensitivity reactions, including anaphylaxis, reported rarely.1


Dyspnea, cyanosis, respiratory failure, urticaria, pruritus, angioedema, hypotonia, and unresponsiveness also reported.1


If a severe hypersensitivity reaction occurs, discontinue palivizumab and initiate appropriate supportive care and therapy (e.g., epinephrine).1 Palivizumab may be continued with caution in patients who experience a milder reaction.1


General Precautions


Administration Precautions

For IM use only.1 Use caution in patients with thrombocytopenia or any coagulation disorder.1


Specific Populations


Pregnancy

Category C.1 Not indicated in adults; used only in pediatric patients who would not be of childbearing potential.1


Lactation

Not known whether distributed into milk.37 Not indicated in adults; used only in pediatric patients who would not be of lactating potential.1


Common Adverse Effects


Upper respiratory tract infection, otitis media, fever, rhinitis, hernia, elevated serum AST concentration.1


Interactions for Synagis


Formal studies have not been conducted to evaluate potential interactions between palivizumab and other drugs.1


Specific Drugs















Drug



Interaction



Bronchodilators



Not specifically studied, but no apparent increase in adverse effects when used concomitantly1



Corticosteroids



Not specifically studied, but no apparent increase in adverse effects when used concomitantly1



Vaccines



No evidence that palivizumab interferes with the immune response to vaccines;1 8 no apparent increase in adverse effects when given concomitantly with routine childhood vaccines1


Synagis Pharmacokinetics


Absorption


Bioavailability


Well absorbed following IM injection in infants.5 37


Plasma Concentrations


Concentrations >40 mcg/mL attained within 2 days after a single 15-mg/kg IM dose; peak concentrations attained within 5–7 days after a dose.5 37


Monthly 15-mg/kg IM doses usually adequate to maintain trough serum concentrations exceeding the ideal target throughout the dosing period (except in children undergoing cardiopulmonary bypass).4 5 Lower doses (i.e., 3 or 10 mg/kg IV, 5 or 10 mg/kg IM) result in inadequate trough concentrations.4 5


Surgical procedures involving cardiopulmonary bypass result in a mean 58% decrease in serum palivizumab concentrations.1 51 (See Dosage under Dosage and Administration.)


Elimination


Half-life


Pediatric patients ≤24 months of age (including patients ≤6 months of age born at ≤35 weeks’ gestation): 19–27 days.1 4 5


Stability


Storage


Parenteral


Injection

2–8°C in original container; do not freeze.1


Actions and SpectrumActions



  • A highly selective antiviral agent active only against RSV.1 2 3 4 5 6 7 8




  • Potent, RSV-neutralizing, monoclonal antibody that neutralizes and inhibits fusion of RSV,1 2 7 resulting in inhibition of viral replication.1




  • Active against both major strains of RSV (subgroup A and B).1 2 In vivo neutralizing activity of the drug was confirmed in a clinical trial in RSV-infected pediatric patients as evidenced by lower recovery of RSV from lower respiratory tract secretions in palivizumab-treated patients compared with placebo recipients.1 38




  • Evidence from animal studies indicates palivizumab does not interfere with in vivo development of a protective immune response to RSV.2




  • All clinical isolates of RSV subgroup A and B tested to date have been susceptible to palivizumab.1 2




  • Animal studies indicate that exposure of RSV to subinhibitory palivizumab concentrations does not enhance viral replication or pathology and does not promote emergence of resistant variants; palivizumab appeared to protect the animals against infection from subsequent RSV challenge despite systemic clearance of the drug.2 However, escape mutants (resistant viruses) have been associated with other monoclonal antibodies and the possibility that they could occur with palivizumab should be considered.8



Advice to Patients



  • Importance of continuing palivizumab prophylaxis in high-risk infants once monthly for the duration of the RSV season.1




  • Importance of contacting clinician if possible symptoms of a hypersensitivity reaction occur (e.g., dyspnea, cyanosis, respiratory failure, urticaria, pruritus, angioedema, hypotonia, unresponsiveness).1




  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products, and any concomitant illnesses.




  • Importance of advising caregivers of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


















Palivizumab

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Parenteral



Injection, for IM use only



50 mg/0.5 mL



Synagis (preservative-free)



MedImmune, (also marketed by Ross)



100 mg/1 mL



Synagis (preservative-free)



MedImmune, (also marketed by Ross)



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions June 2006. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



1. MedImmune, Inc. Synagis (palivizumab) for intramuscular administration prescribing information. Gaithersburg, MD; 2004 Jul 23.



2. Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176:1215-24. [PubMed 9359721]



3. Committee on Infectious Diseases, American Academy of Pediatrics. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:523-8.



4. Subramanian KNS, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998; 17:110-15. [IDIS 401101] [PubMed 9493805]



5. Sáez-Llorens X, Casta˜no E, Null D et al. Safety and efficacy of intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998; 17:787-91. [IDIS 415465] [PubMed 9779762]



6. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-7.



7. Storch GA. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics. 1998; 102:648-51. [IDIS 413527] [PubMed 9738192]



8. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003; 112:1442-6. [PubMed 14654627]



9. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics. 1997; 99:645-50. [IDIS 383952] [PubMed 9093323]



10. Massachusetts Public Health Biologic Laboratories. RespiGam [respiratory syncytial virus immune globulin intravenous (human), (RSV-IGIV)] liquid formulation, solvent detergent treated prescribing information. Boston, MA; 2000 May.



11. Massachusetts Public Health Biologic Laboratories. RespiGam [respiratory syncytial virus immune globulin intravenous (human), (RSV-IGIV)] product monograph. Boston, MA; 1996 May.



12. Groothuis JR, Simoes EAF, Levin MJ et al et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993; 329:1524-30. [IDIS 322264] [PubMed 8413475]



13. McIntosh K. Respiratory syncytial virus—successful immunoprophylaxis at last. N Engl J Med. 1993; 329:1572- 3. [PubMed 8413482]



14. Siber GR, Leombruno D, Leszczynski J et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994; 169:1368-73. [PubMed 8195619]



15. Connor E, Top F, Kramer A et al et al. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997; 99:93-9. [IDIS 378350] [PubMed 8989345]



16. La Via WV, Marks MI, Stutman HR. Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention. J Pediatr. 1992; 121:503-10. [PubMed 1403380]



17. Groothuis JR, Simoes EAF, Hemming VG et al et al. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics. 1995; 95:463-7. [IDIS 345809] [PubMed 7700741]



18. Groothuis JR. Role of antibody and the use of respiratory syncytial virus immunoglobulin in the prevention of respiratory syncytial virus disease in preterm infants with and without bronchopulmonary dysplasia. Pediatr Infect Dis J. 1994; 13:454-8. [PubMed 8072836]



19. Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. Pediatr Infect Dis J. 1994; 13:449-53. [PubMed 8072835]



20. Groothuis JR. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children. J Pediatr. 1994; 124(Suppl):S28-32. [IDIS 329428] [PubMed 8169755]



21. Levin MJ. Treatment and prevention options for respiratory syncytial virus infections. J Pediatr. 1994; 24(Suppl):S22-7.



22. Meissner HC. Economic impact of viral respiratory disease in children. J Pediatr. 1994; 124(Suppl):S17-21.



23. Hemming VG. Viral respiratory diseases in children: classification, etiology, epidemiology, and risk factors. J Pediatr. 1994; 124(Suppl):S13-6. [PubMed 8169752]



24. Hemming VG, moderator. Questions and answers. Proceedings of First Annual Saul Krugman Symposium on Pediatric Viral Infections: Viral Respiratory Diseases in Children. J Pediatr. 1994; 124(Suppl):S33-4.



25. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995:1501-19.



26. Hemming VG, Prince GA, Groothuis JR et al. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev. 1995; 8:22-33. [PubMed 7704893]



27. Meissner HC, Welliver RC, Chartrand SA et al. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J. 1996; 15:1059-68. [IDIS 378154] [PubMed 8970212]



28. Gilchrist S, Török TJ, Gary HE Jr et al. National surveillance for respiratory syncytial virus, United States, 1985–1990. J Infect Dis. 1994; 170:986-90. [PubMed 7930745]



29. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care. 1996; 2:851-61.



30. Murguia de Sierra T, Kumar ML, Wasser TE et al. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr. 1993; 122:787-91. [PubMed 8496762]



31. Whimbey E, Champlin RE, Couch RB et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996; 22:778-82. [PubMed 8722930]



32. Harrington RD, Hooton TM, Hackman RC et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992; 165:987-93. [IDIS 297152] [PubMed 1583345]



33. Whimbey E, Couch RB, Englund JA et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995; 21:376-9. [IDIS 351726] [PubMed 8562747]



34. McConnochie KM, Hall CB, Walsh EE et al. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr. 1990; 117:52-62. [PubMed 2115082]



35. King JC Jr, Burke AR, Clemens JD et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J. 1993; 12:733-9. [PubMed 8414800]



36. Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986; 315:77-81. [IDIS 217676] [PubMed 3724802]



37. Medimmune, Inc, Gaithersburg, MD: Personal communication.



38. DeVincenzo JP, Malley R, Ramilo O et al. Viral concentration in upper and lower respiratory secretions from respiratory syncytial virus (RSV) infected children treated with RSV monoclonal antibody (MEDI 493). Pediatr Res. 1998; 43:144A.



39. Moler FW, Brown RW, Faix RG et al. Comments on palivizumab (Synagis). Pediatrics. 1999; 103:495-7. [IDIS 440422] [PubMed 9925848]



40. Hall CB, Stevens TP, Swantz RJ et al. Development of local guidelines for prevention of respiratory syncytial viral infections. Pediatr Infect Dis J. 1999; 18:850-3. [IDIS 437579] [PubMed 10530578]



41. Lee SL, Robinson JL. Questions about palivizumab (Synagis). Pediatrics. 1999; 103:535. [IDIS 440426] [PubMed 10026069]



42. Connor EM, Carlin D, Top FJ Jr. Questions about palivizumab (Synagis). Pediatrics. 1999; 103:535. [IDIS 440426] [PubMed 10026069]



43. Berg T. Immunoglobulin levels in infants with low birth weights. Acta Paediatr Scand. 1968; 57:369-376. [PubMed 4178846]



44. Evans HE, Akpata SO, Glass L. Serum immunoglobulin levels in pre-mature and full-term infants. Am J Clin Pathol. 1971; 56:416-8. [PubMed 4999328]



45. Haworth JC, Norris M, Dilling L. A study of the immunoglobulins in premature infants. Arch Dis Child. 1965; 40:243-50. [PubMed 21032417]



46. Hobbs JR and Davis JA. Serum IgG-globulin levels and gestational age in premature babies. Lancet. 1967; 1:757-59. [PubMed 4164125]



47. Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: a survey. Pediatrics. 1966; 37:715-27. [PubMed 4956666]



48. Yeung CY and Hobbs JR. Serum-gamma G-globulin levels in normal, premature, post-mature and “small-for-dates” newborn babies. Lancet. 1968; 1:1167-72. [PubMed 4172289]



49. Grier CE, Howe BJ. Economic impact of pneumonia due to respiratory syncytial virus (RSV) infection. ICAAC 35th annual meeting. San Francisco, CA, 1995. Abstract No. N9.



50. Meissuer HC, Welliver RC, Chartrand SA et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999; 18:223-31. [IDIS 426689] [PubMed 10093942]



51. Feltes TF, Cabalka, AK, Meissner C et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143:532-40. [PubMed 14571236]



More Synagis resources


  • Synagis Side Effects (in more detail)
  • Synagis Use in Pregnancy & Breastfeeding
  • Synagis Support Group
  • 0 Reviews for Synagis - Add your own review/rating


  • Synagis Prescribing Information (FDA)

  • Synagis Consumer Overview

  • Synagis Advanced Consumer (Micromedex) - Includes Dosage Information

  • Synagis MedFacts Consumer Leaflet (Wolters Kluwer)

  • Palivizumab Professional Patient Advice (Wolters Kluwer)



Compare Synagis with other medications


  • Respiratory Syncytial Virus

Friday, 14 September 2012

Aleve



Generic Name: naproxen (na PROX en)

Brand Names: Aleve, Aleve Caplet, Aleve Easy Open Arthritis, Aleve Gelcap, Anaprox, Anaprox-DS, Comfort Pac with Naproxen, EC-Naprosyn, Leader Naproxen Sodium, Midol Extended Relief, Naprelan 375, Naprelan 500, Naprelan 750, Naprosyn


What is naproxen?

Naproxen is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Naproxen works by reducing hormones that cause inflammation and pain in the body.


Naproxen is used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.


Naproxen may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about naproxen?


This medicine can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use naproxen. Do not use this medicine just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).


Seek emergency medical help if you have symptoms of heart or circulation problems, such as chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.


This medicine can also increase your risk of serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and gastrointestinal effects can occur without warning at any time while you are taking naproxen. Older adults may have an even greater risk of these serious gastrointestinal side effects.


Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.


Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to naproxen (such as ibuprofen or ketoprofen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, or ketoprofen. Do not drink alcohol while taking naproxen. Alcohol can increase the risk of stomach bleeding caused by naproxen. Avoid prolonged exposure to sunlight. Naproxen can make your skin more sensitive to sunlight, and a sunburn may result.

What should I discuss with my healthcare provider before taking naproxen?


Taking an NSAID can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use an NSAID. Do not use this medicine just before or after having heart bypass surgery (also called coronary artery bypass graft, or CABG).


NSAIDs can also increase your risk of serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and gastrointestinal effects can occur without warning at any time while you are taking an NSAID. Older adults may have an even greater risk of these serious gastrointestinal side effects.


Do not use this medication if you are allergic to naproxen, or if you have a history of allergic reaction to aspirin or other NSAIDs.

If you have any of these other conditions, you may need a dose adjustment or special tests to safely use naproxen:



  • a history of heart attack, stroke, or blood clot;




  • heart disease, congestive heart failure, high blood pressure;




  • a history of stomach ulcers or bleeding;



  • liver or kidney disease;


  • asthma;




  • polyps in your nose;




  • a bleeding or blood clotting disorder; or




  • if you smoke.




FDA pregnancy category C. Before using naproxen, tell your doctor if you are pregnant or plan to become pregnant during treatment. Taking naproxen during the last 3 months of pregnancy may result in birth defects. Do not take naproxen during pregnancy unless your doctor has told you to. Naproxen can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not give this medicine to a child younger than 2 years old without the advice of a doctor.

How should I take naproxen?


Take this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts, or use it for longer than recommended.


EC-Naprosyn is a slower-acting form of naproxen and this brand should be used only for treating arthritis or ankylosing spondylitis. Follow your doctor's instructions.


Do not crush, chew, or break an extended-release or enteric-coated tablet. Swallow the pill whole. The extended-release pill is specially made to release medicine slowly in the body. Breaking the pill would cause too much of the drug to be released at one time. The enteric-coated pill has a special coating to protect your stomach. Breaking the pill could damage this coating. Shake the oral suspension (liquid) well just before you measure a dose. To be sure you get the correct dose, measure the liquid with a marked measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

If you take naproxen for a long period of time, your doctor may want to check you on a regular basis to make sure this medication is not causing harmful effects. Do not miss any scheduled visits to your doctor.


Store naproxen at room temperature away from moisture and heat.

What happens if I miss a dose?


Since naproxen is sometimes taken only when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include nausea, vomiting, stomach pain, confusion, drowsiness, black or bloody stools, coughing up blood, shallow breathing, fainting, or coma.

What should I avoid while taking naproxen?


Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to naproxen (such as ibuprofen or ketoprofen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, or ketoprofen. Do not drink alcohol while taking naproxen. Alcohol can increase the risk of stomach bleeding caused by naproxen. Avoid prolonged exposure to sunlight. Naproxen can make your skin more sensitive to sunlight, and a sunburn may result. Wear protective clothing and use sunscreen (SPF 15 or higher) when you are outdoors.

Naproxen side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking naproxen and seek medical attention or call your doctor at once if you have any of these serious side effects:

  • chest pain, weakness, shortness of breath, slurred speech, problems with vision or balance;




  • black, bloody, or tarry stools;




  • coughing up blood or vomit that looks like coffee grounds;




  • swelling or rapid weight gain;




  • urinating less than usual or not at all;




  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);




  • fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;




  • bruising, severe tingling, numbness, pain, muscle weakness; or




  • fever, headache, neck stiffness, chills, increased sensitivity to light, purple spots on the skin, and/or seizure (convulsions).



Less serious side effects may include:



  • upset stomach, mild heartburn or stomach pain, diarrhea, constipation;




  • bloating, gas;




  • dizziness, headache, nervousness;




  • skin itching or rash;




  • blurred vision; or




  • ringing in your ears.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect naproxen?


Tell your doctor if you are taking an antidepressant such as citalopram (Celexa), duloxetine (Cymbalta), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, Symbyax), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), or venlafaxine (Effexor). Taking any of these drugs with naproxen may cause you to bruise or bleed easily.


Tell your doctor about all other medicines you use, especially:



  • a blood thinner such as warfarin (Coumadin);




  • lithium (Eskalith, Lithobid);




  • methotrexate (Rheumatrex, Trexall);




  • diuretics (water pills) such as furosemide (Lasix);




  • steroids (prednisone and others);




  • aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen (Motrin, Advil), diclofenac (Cataflam, Voltaren), etodolac (Lodine), indomethacin (Indocin), naproxen (Aleve, Naprosyn), meloxicam (Mobic), piroxicam (Feldene), and others; or




  • an ACE inhibitor such as benazepril (Lotensin), captopril (Capoten), fosinopril (Monopril), enalapril (Vasotec), lisinopril (Prinivil, Zestril), ramipril (Altace), and others.



This list is not complete and there may be other drugs that can interact with naproxen. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Aleve resources


  • Aleve Side Effects (in more detail)
  • Aleve Use in Pregnancy & Breastfeeding
  • Aleve Drug Interactions
  • Aleve Support Group
  • 33 Reviews for Aleve - Add your own review/rating


  • Aleve Advanced Consumer (Micromedex) - Includes Dosage Information

  • Aleve Consumer Overview

  • Aleve MedFacts Consumer Leaflet (Wolters Kluwer)

  • Naproxen Prescribing Information (FDA)

  • Naproxen Monograph (AHFS DI)

  • Naproxen Professional Patient Advice (Wolters Kluwer)

  • Anaprox MedFacts Consumer Leaflet (Wolters Kluwer)

  • EC-Naprosyn Enteric-Coated Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Naprosyn Consumer Overview

  • Naprosyn Prescribing Information (FDA)



Compare Aleve with other medications


  • Ankylosing Spondylitis
  • Aseptic Necrosis
  • Back Pain
  • Bursitis
  • Costochondritis
  • Diffuse Idiopathic Skeletal Hyperostosis
  • Dysautonomia
  • Fever
  • Frozen Shoulder
  • Gout, Acute
  • Headache
  • Juvenile Rheumatoid Arthritis
  • Muscle Pain
  • Osteoarthritis
  • Pain
  • Period Pain
  • Rheumatoid Arthritis
  • Sciatica
  • Spondylolisthesis
  • Tendonitis


Where can I get more information?


  • Your pharmacist can provide more information about naproxen.

See also: Aleve side effects (in more detail)


Thursday, 13 September 2012

Noradrenaline (Norepinephrine) 1:1000 or Levophed





1. Name Of The Medicinal Product



Noradrenaline (Norepinephrine) 1:1000 or Levophed



concentrate for solution for infusion


2. Qualitative And Quantitative Composition



Noradrenaline Tartrate 2 mg/ml



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Concentrate for solution for infusion



4. Clinical Particulars



4.1 Therapeutic Indications



Norepinephrine 1:1000 is recommended for use as an emergency measure in the restoration of blood pressure in cases of acute hypotension.



4.2 Posology And Method Of Administration



Route of Administration:



For intravenous use.



Route and method of infusion:



Norepinephrine 1:1000 should be administered in a diluted solution via a central venous catheter.



The infusion should be at a controlled rate using either a syringe pump or an infusion pump or a drip counter.



Dilution instructions:



Norepinephrine 1:1000 should be diluted either with dextrose 5%, or with isotonic dextrose saline.



Adults:



Either add 2 ml of Norepinephrine 1:1000 to 48 ml 5% dextrose for administration by syringe pump, or add 20 ml of Norepinephrine 1:1000 to 480 ml 5% dextrose for administration by drip counter.



In both cases the final concentration of the infusion solution is 80 mg/litre norepinephrine tartrate, which is equivalent to 40 mg/litre norepinephrine base. If other dilutions are used check the calculation carefully before starting treatment.



Initial rate of infusion:



The initial rate of infusion should be between 10 ml/hour and 20 ml/hour (0.16 ml/min to 0.33 ml/min). This is equivalent to 0.8 mg/hr to 1.6 mg/hr norepinephrine tartrate (or 0.4 mg/hr to 0.8 mg/hr norepinephrine base).



Titration of dose:



Once an infusion of norepinephrine has been established the dose should be titrated according to the pressor effect observed. There is great individual variation in the dose required to attain and maintain normotension. The aim should be to establish a low normal systolic blood pressure (100-120 mm Hg) or to achieve an adequate mean arterial blood pressure (greater than 80 mm Hg).



Duration of Treatment and Monitoring:



Norepinephrine should be continued for as long as vasoactive drug support is indicated. The patient should be monitored carefully for the duration of norepinephrine therapy.



Elderly.



As for adults but see Precautions.



Children:



Not recommended.



4.3 Contraindications



The use of pressor amines during cyclopropane or halothane anaesthesia may cause serious cardiac arrhythmias. Because of the possibility of increasing the risk of ventricular fibrillation, norepinephrine should be used with caution in patients receiving these or any other cardiac sensitising agent or who exhibit profound hypoxia or hypercarbia.



Particular caution should be observed in patients with coronary, mesenteric or peripheral vascular thrombosis because norepinephrine may increase the ischemia and extend the area of infarction. Similar caution should be observed in patients with hypotension following myocardial infarction and in patients with Prinzmetal's variant angina.



4.4 Special Warnings And Precautions For Use



Norepinephrine should be used only in conjunction with appropriate blood volume replacement. When infusing norepinephrine, the blood pressure and rate of flow should be checked frequently to avoid hypertension. Extravasation of the solution may cause local tissue necrosis. The infusion site should be checked frequently. If extravasation occurs, the area should be infiltrated with phentolamine without delay.



It has been suggested that phentolamine may be added directly to the infusion flask to act as an antidote against sloughing without affecting the vasopressor activity of norepinephrine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Norepinephrine should be used with extreme caution in patients receiving monoamine oxidase inhibitors or tricyclic antidepressants because severe, prolonged hypertension may result. The elderly may be especially sensitive to the effects of norepinephrine.



4.6 Pregnancy And Lactation



Norepinephrine may impair placental perfusion and induce foetal bradycardia. It may also exert a contractile effect on the pregnant uterus and lead to foetal asphyxia in late pregnancy. These possible risks to the foetus should therefore be weighed against the potential benefit to the mother.



4.7 Effects On Ability To Drive And Use Machines



None stated.



4.8 Undesirable Effects



Hypertension may occur, which may be associated with bradycardia as well as headache and peripheral ischemia, including gangrene of the extremities. Cardiac arrhythmias may arise when norepinephrine is used in conjunction with cardiac sensitising agents, and may be more likely in patients with hypoxia or hypercarbia. Prolonged administration may result in plasma volume depletion.



4.9 Overdose



Overdosage may result in severe hypertension, reflex bradycardia, marked increase in peripheral resistance and decreased cardiac output. These may be accompanied by violent headache, photophobia, retrosternal pain, pallor, intense sweating and vomiting. In the event of overdosage, treatment should be withdrawn and appropriate corrective treatment initiated.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Adrenergic and dopaminergic agents, ATC code: C01CA03



The vascular effects of norepinephrine in the doses usually used clinically result from the simultaneous stimulation of alpha and beta adrenergic receptors in the heart and vascular system. Except in the heart, its action is predominantly on the alpha receptors. This results in an increase in the force (and in the absence of vagal inhibition) in the rate of myocardial contraction. Peripheral resistance increases and diastolic and systolic pressures are raised.



5.2 Pharmacokinetic Properties



Up to 16% of an intravenous dose is excreted unchanged in the urine with methylated and deaminated metabolites in free and conjugated forms.



5.3 Preclinical Safety Data



None stated.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sodium Chloride



Water for Injections.



This medicinal product contains sodium



− 2 ml container contains 0.29 mmol (or 6.7 mg) sodium per container.



− 4 ml container contains 0.58 mmol (or 13.3 mg) sodium per container.



− 20 ml container contains 2.9 mmol (or 67 mg) sodium per container.



To be taken into consideration by patients on a controlled sodium diet.



6.2 Incompatibilities



Infusion solutions containing norepinephrine tartrate have been reported to be incompatible with the following substances: alkalis and oxidising agents, barbiturates, chlorpheniramine, chlorothiazide, nitrofurantoin, novobiocin, phenytoin, sodium bicarbonate, sodium iodide, streptomycin.



6.3 Shelf Life



18 months.



6.4 Special Precautions For Storage



Do not store above 25°C. Keep the container in the outer carton.



6.5 Nature And Contents Of Container



2ml, 4ml and 20ml ampoules packed in boxes of 5.



6.6 Special Precautions For Disposal And Other Handling



Any unused product or waste material should be disposed of in accordance with local requirements.



7. Marketing Authorisation Holder



Hospira Enterprises BV.



Randstad 22-11, 1316 BN Almere,



The Netherlands



8. Marketing Authorisation Number(S)



PL 23061/0006



9. Date Of First Authorisation/Renewal Of The Authorisation



1 July 2005



10. Date Of Revision Of The Text



October 2010